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ABSTRACT 
 Dysregulated microRNA (miRNA) expression is a well-established feature of human 
cancer. However, the role of specific miRNAs in determining cancer outcomes remains unclear. 
Using Level 3 expression data from the Cancer Genome Atlas (TCGA), we identified 61 
miRNAs that are associated with overall survival in 469 ovarian cancers profiled by microarray 
(p<0.01). We also identified 12 miRNAs that are associated with survival when miRNAs were 
profiled in the same specimens using Next Generation Sequencing (miRNA-Seq) (p<0.01). 
Surprisingly, only 1 miRNA transcript is associated with ovarian cancer survival in both datasets. 
Our analyses indicate that this discrepancy is due to the fact that miRNA levels reported by the 
two platforms correlate poorly, even after correcting for potential issues inherent to signal 
detection algorithms. Further investigation is warranted. 
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INTRODUCTION 
 MicroRNAs (miRNAs) are endogenous RNA transcripts that regulate diverse patterns of 
gene expression.1 Most human miRNAs are transcribed as long precursors known as pri-
miRNAs. Starting in the nucleus, pri-miRNAs undergo a series of processing events that 
ultimately result in the cytoplasmic release of mature transcripts ~22 nucleotides in length. 
Mature miRNAs catalyze translational inhibition by directly binding to messenger RNAs 
(mRNAs) and promoting their degradation.2 Recent data also indicate that miRNAs can inhibit 
translation independent of their ability to induce mRNA degradation. 
Patterns of miRNA expression have now been extensively profiled in many different human 
tissues. It is now clear that dysregulated miRNA expression is a feature of many different 
cancers, including carcinomas of the breast, ovary and lung.3-5 However, determining the 
mechanisms by which individual miRNAs contribute to cancer outcomes remains a key 
challenge for biologists hoping to exploit their power. Recently, the Cancer Genome Atlas 
Consortium (TCGA) reported that ovarian cancers cluster into distinct molecular subtypes based 
on their patterns of gene and microRNA expression.6 However, we have discovered an alarming 
lack of consistency between the microRNA (miRNA) expression profiles initially used by the 
TCGA and a subsequent profile of miRNA expression generated by this group for the same 
ovarian cancer specimens using miRNA-Seq. As these observations challenge the validity of 
the underlying data, they also challenge scientific discoveries based on this data.  
 
RESULTS 
To delineate miRNAs associated with ovarian cancer patient survival, we performed a 
univariate Cox regression analysis using Level 3 TCGA miRNA data for 469 ovarian cancers 
profiled using Agilent microarray technology. We found that 61 mature miRNAs are significantly 
associated with ovarian cancer survival (p<0.01) (Figure 1A). Of these, miR-505, miR-652 and 
miR-551b* demonstrate the most robust associations. Hazard ratios (HR) calculated for these 
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miRNAs were -1.73, -1.8, and 9.3, respectively, indicating that each miRNA potentially plays an 
important role in determining ovarian cancer survival.  
To validate these observations, we next interrogated a second dataset of miRNA expression 
generated for the same ovarian cancer specimens using Next Generation Sequencing (miRNA-
Seq). The TCGA ovarian cancer project is unique in that miRNA expression has been profiled 
using both miRNA array and miRNA-Seq. Use of these technically distinct platforms creates a 
unique opportunity to validate discoveries made using one dataset against the other. Ideally, the 
results obtained should correlate tightly. Using Cox Proportional Hazards analysis, we found 
that 12 miRNA transcripts are associated with survival when miRNAs were profiled in ovarian 
cancers using miRNA-Seq (Figure 1B). However, the hazard ratios estimated for the 12 
miRNAs identified from miRNA-Seq data are all very close to 1.0. Surprisingly, only miR-652 is 
associated with survival in both the miRNA-Seq and microarray datasets. To correct for multiple 
hypothesis testing, we adjusted our Cox model p-values using Benjamini–Hochberg procedure.7  
After completing these analyses, no miRNAs are correlated with survival in both datasets when 
the false discovery rate was set at 10%.  
To elucidate potential causes for this unexpected discrepancy, we examined the 
reproducibility of miRNA expression between the two TCGA files that describe this data. 
Pearson correlation coefficients (r) were calculated for each of the 359 mature human miRNAs 
for which Level 3 expression data was available in both the miRNA-Seq and microarray 
databases. We found that correlation coefficients for levels of individual miRNAs reported by 
each technique varied widely. For example, miR-505 is the miRNA most robustly associated 
with patient outcome in our analyses of the miRNA array data (HR = -1.7, p< 9e-5). However, 
when assessed using sequencing data, the hazard ratio for mir-505 was 0.998 (p=0.03). Levels 
of miR-505 measured by miRNA-array and miRNA-Seq data correlated only modestly (r = 0.59) 
(Figure 2B). Discrepancies were also observed in a number of other miRNAs that have been 
previously implicated in ovarian cancer, such as miR-143.8 The correlation coefficient for miR-
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143 in our analyses was 0.39 (Figure 2C). Another miRNA well-studied in ovarian cancer is 
miR-141, which has been previously reported to target p38α and modulate the oxidative stress 
response.9,10 However, the correlation between levels of miR-141 in TCGA microarray and 
miRNA-Seq expression data is only 0.32 (Figure 2D). Overall, we found that correlation 
coefficients for ~72% of miRNAs profiled in both datasets were ≤ 0.5 (Figure 3A, 3C), indicating 
poor reproducibility. In contrast, only 22% of the mRNAs measured by Agilent microarray and 
Illumina HiSeq using the same ovarian cancer specimens correlate poorly (r ≤ 0.5; Figure 3B, 
3C). Thus, the discrepancy we report here appears to be limited to the TCGA miRNA dataset.  
One potential cause for poor reproducibility may be the signal detection algorithm used to 
report levels of miRNA expression. Level 3 TCGA miRNA data are reported in two formats. The 
first, labeled as a “Quantification Data," reports levels for individual human miRNAs. However, 
one of the advantages of miRNA-Seq is that transcripts retrieved by this technique can be 
precisely mapped. A second file, labeled as “Isoform Data," has also been released by the 
TCGA. This file reports read counts for transcripts according to their genomic location. As part 
of this file, transcripts are identified as either mature miRNA, miRNA* (3p arms of human 
miRNAs), stem-loop transcript or precursor. While working through this data, we learned that 
miRNA levels reported in the TCGA quantification file include read counts for miRNA precursors 
as well as mature miRNAs. Because miRNA precursors typically lack biologic activity, inclusion 
of precursors with counts for mature miRNAs could confound survival analyses. To address this 
issue, we retrieved read counts for mature miRNAs only from the isoform data file and repeated 
our analyses. However, the proportion of miRNA correlation coefficients ≤ 0.5 remained as high 
as 71% despite the use of this more precisely defined data. 
A second possible explanation for the discrepancy we observed might be that correlations 
between measures of miRNA expression depend on the frequency with which individual miRNA 
transcripts are expressed. If so, infrequently expressed miRNAs might be reported by one or 
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both of the platforms used to profile miRNA expression randomly or inaccurately. To explore this 
hypothesis, we re-calculated correlation coefficients for each miRNA identified by both platforms 
after excluding any transcript in the miRNA-Seq dataset with a read count less than 5. This 
reduced the number of distinct miRNAs available for analysis in the miRNA-Seq data file from 
705 to 380. However, the proportion of miRNAs with correlation coefficients ≤ 0.5 also 
decreased from 72% to 56%. Similarly removing poorly expressed transcripts from the pool of 
mRNAs profiled by Illumina HiSeq reduces the proportion of mRNAs whose correlation 
coefficients ≤ 0.5 from 22% to 20%. These observations indicate that problems detecting 
infrequently expressed miRNA may impact the ability or one or both platforms to reliably report 
miRNA expression. However, the fact that more than half of miRNA transcripts still had 
correlation coefficients ≤ 0.5 even after correcting for this issue indicates that poorly expressed 
transcripts are not solely responsible for the discordant patterns of miRNA expression reported 
by the two platforms. 
 
DISCUSSION 
Much to our surprise, our analyses indicate that the microRNAs associated with survival in 
ovarian cancer depend highly on whether specimens were profiled by the TCGA using 
microarray or miRNA-Seq. Our analyses indicate that this discrepancy exists because miRNA-
Seq and microarray have generated very different profiles of miRNA expression, even though 
the data is based on the same ovarian cancer specimens. We do not currently have a clear 
explanation for why miRNA expression profiles reported by the TCGA are discordant. However, 
understanding this discrepancy will ultimately be important for identifying which miRNAs if any 
are important for determining ovarian cancer outcomes. 
A variety of DNA microarray technologies have been previously validated by investigators 
examining within platform and cross-platform reproducibility.11-13 Spearman correlation 
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coefficients reported in these studies range from 0.59 to 0.94 with a mean of 0.82. These results 
are similar to what we have observed for correlations between patterns of gene expression 
profiled using microarray and Illumina HiSeq platforms by the TCGA. Both miRNA-Seq and 
microarray technologies are associated with multiple technical limitations that might account for 
the differences we have observed. For example, cross-hybridization is a well-recognized issue 
that can reduce signal specificity when profiling RNA transcripts by microarray.14 However, it 
seems unlikely that cross-hybridization can fully explain the discrepancy we observed, as the 
number of transcripts correlated with survival by array is greater than the number associated 
with survival by miRNA-Seq. One alternate explanation might be that the signal extraction 
algorithm used to analyze miRNA-Seq data does not accurately report miRNA levels. In 
general, miRNA-Seq allows for precise transcript mapping with much greater confidence. The 
signal extraction algorithm currently used by the TCGA to report miRNA levels includes read 
counts for both a mature miRNA and its corresponding precursor. Precursors account for fewer 
than 1% of the total miRNA counts in the TCGA isoform file, likely reflecting the use of size-
fractionated total RNA to prepare small RNA libraries for miRNA-Seq.5  Our analyses indicate 
that their inclusion has little bearing on which miRNAs are associated with ovarian cancer 
survival.  
These observations underscore the urgent need for well-defined algorithms for processing 
signals generated by miRNA-Seq and transcriptional profiling platforms. Our understanding is 
that the same analyses have been performed by TCGA for other cancers, including colon, 
breast and lung.15-17 Because miRNA expression in these other cancers has not been profiled 
by microarray, it is not possible to repeat our analyses to determine whether the discrepancy we 
report is observed in other cancers.  
Ultimately, consistent and reliable genomic data is critical for constructing testable 
hypotheses and achieving the full potential of the TCGA. Our observations identify an important 
hazard of which investigators should be aware as they utilize the TCGA miRNA data to study 
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ovarian cancer. This hazard underscores the need to validate observations made with one or 
both of TCGA miRNA datasets. Over the long term, resolution of this discrepancy will be 
important for determining the most effective platform and signal extraction algorithms for 
profiling miRNA expression as part of large scale genomic profiling efforts.  
 
MATERIALS AND METHODS 
Gene and microRNA Expression Data. Level 3 data documenting patterns of gene expression 
for 296 ovarian cancer specimens profiled using Agilent G4502A arrays and Illumina HiSeq 
were downloaded from the TCGA data portal. Level 3 microRNA expression data were also 
retrieved for 469 ovarian cancer specimens profiled using the Agilent 4X15k array and miRNA-
Seq. Level 3 miRNA data profiled by miRNA-Seq were retrieved from both the miRNA 
quantification and isoform files available at the TCGA data portal along with metafiles annotating 
each dataset. Permission to access all data was obtained from the Data Access Committee for 
the National Center for Biotechnology Information Genotypes and Phenotypes Database 
(dbGAP) at the National Institutes of Health. 
Survival Analyses. Coded patient survival data was extracted from the TCGA clinical 
information file. A Cox Proportional Hazards model was used to estimate association between 
levels of individual miRNAs. Patient survival was calculated as time in months elapsed from 
date of diagnosis until date of last contact. 
Statistical Analyses. Spearman’s rank correlation coefficients, histograms, and the empirical 
cumulative distribution were computed and plotted for each miRNA and gene using r. 
Sequencing data were log transformed for plotting. Both direct read counts and counts 
normalized according to millions of miRNAs were examined as part of our analyses. All 
analyses were performed using both raw and normalized read counts reported as part of the 
TCGA miRNA-Seq datasets. 
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FIGURES 
 
FIGURE 1. MicroRNAs associated with ovarian cancer survival. P-value plots of univariate 
Cox regression for microRNAs associated with ovarian cancer survival identified by microarray 
(A) or miRNA-Seq (B) data. P-value < 0.01 (Solid line). False discovery rate (FDR) < 0.1 (Dotted 
line). In both A&B, blue dots indicate miRNAs associated with survival by miRNA array, while 
red dots indicate miRNAs associated with survival by miR-Seq. Green stars are miRNAs 
associated with survival in both datasets. 
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FIGURE 2. Scatter-plots of microRNA expression measured by microarray and miRNA-
Seq. (A) miR-98, (B) miR-505 (C) miR-143 and (D) miR-141.   
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FIGURE 3. Distribution of correlations between microarray and sequencing profiles for 
miRNA and gene expression. (A) Histogram of correlation coefficients for individual miRNAs 
measured by miRNA-Seq and miRNA array. (B) Histogram of correlation coefficients for mRNAs 
profiled by Illumina HiSeq and mRNA array. (C) The empirical cumulative distribution function 
(ECDF) of the correlation between array and sequencing for miRNA (black) and mRNA (gray) 
measurements. Nearly, 72% of miRNAs demonstrate a correlation coefficient ≤ 0.5 whereas 
22% of RNAs have a correlation coefficient ≤ 0.5.  
